- Home
- KYMR vs PTGX Comparison
KYMR vs PTGX Comparison
Compare KYMR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- PTGX
- Stock Information
- Founded
- KYMR 2015
- PTGX 2006
- Country
- KYMR United States
- PTGX United States
- Employees
- KYMR N/A
- PTGX N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- KYMR Health Care
- PTGX Health Care
- Exchange
- KYMR Nasdaq
- PTGX Nasdaq
- Market Cap
- KYMR 3.1B
- PTGX 3.3B
- IPO Year
- KYMR 2020
- PTGX 2016
- Fundamental
- Price
- KYMR $44.91
- PTGX $55.32
- Analyst Decision
- KYMR Strong Buy
- PTGX Strong Buy
- Analyst Count
- KYMR 16
- PTGX 9
- Target Price
- KYMR $58.94
- PTGX $67.11
- AVG Volume (30 Days)
- KYMR 875.7K
- PTGX 900.6K
- Earning Date
- KYMR 08-06-2025
- PTGX 08-05-2025
- Dividend Yield
- KYMR N/A
- PTGX N/A
- EPS Growth
- KYMR N/A
- PTGX N/A
- EPS
- KYMR N/A
- PTGX 0.86
- Revenue
- KYMR $58,885,000.00
- PTGX $207,801,000.00
- Revenue This Year
- KYMR $58.26
- PTGX N/A
- Revenue Next Year
- KYMR N/A
- PTGX $53.09
- P/E Ratio
- KYMR N/A
- PTGX $63.65
- Revenue Growth
- KYMR N/A
- PTGX N/A
- 52 Week Low
- KYMR $19.45
- PTGX $32.50
- 52 Week High
- KYMR $53.27
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- KYMR 56.82
- PTGX 61.17
- Support Level
- KYMR $43.56
- PTGX $49.38
- Resistance Level
- KYMR $45.83
- PTGX $51.51
- Average True Range (ATR)
- KYMR 1.77
- PTGX 2.02
- MACD
- KYMR -0.49
- PTGX 0.02
- Stochastic Oscillator
- KYMR 51.65
- PTGX 75.62
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.